Open AccessTreatment patterns and outcomes of patients with advanced malignant pleural mesothelioma in a community practice setting
Author(s) -
David Waterhouse,
Esmond Nwokeji,
Marley Boyd,
John R. Penrod,
Janet L. Espirito,
Nicholas J. Robert,
M. Daumont
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2021-0047
Subject(s) - pemetrexed , medicine , carboplatin , mesothelioma , oncology , nivolumab , regimen , gemcitabine , cisplatin , ipilimumab , chemotherapy , cancer , immunotherapy , pathology
Aim: To assess real-world treatment patterns and outcomes among patients with advanced malignant pleural mesothelioma. Patients & methods: Retrospective database analysis. Results: In all, 469 patients received first-line systemic anticancer therapy (SACT) at community centers. Median follow-up from diagnosis was 11.6 months. Pemetrexed + platinum was the most common first-line SACT; similar proportions of patients received cisplatin or carboplatin with pemetrexed. Only a small proportion of patients received second- and third-line therapies. Median overall survival for first-line SACT was 12.0 months (95% CI: 10.7–14.2). Results were similar with pemetrexed + cisplatin and pemetrexed + carboplatin. Median overall survival with second-line SACT was 6.4 months (95% CI: 5.1–7.6). Conclusion: There is a need for more effective SACTs for advanced malignant pleural mesothelioma.